GlaxoSmithKline To Pay $75M To Settle Patent Suit

Law360, New York (May 25, 2004, 12:00 AM EDT) -- GlaxoSmithKline has agreed to pay $75 million dollars to settle a drug patent lawsuit brought by a consumer group that had accused the U.K. drug maker of using illegal tactics to maintain its patent on the anti-inflammatory drug Relafen and keep a cheaper generic version off the market.

The settlement, which must be approved by the U.S. District Court Judge William G. Young in Boston, is over a lawsuit brought last year by the consumer group Prescription Access Litigation.

PAL, a nationwide coalition of 93 consumer...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.